ÌÇÐÄvlog

Urate as a Predictor of the Rate of Clinical Decline in Parkinson Disease

• Editorial
  Natural Oxidant Balance in Parkinson Disease
  George Perry, PhD; Paula I. Moreira, PhD; Sandra L. Siedlak, BA; Akihiko Nunomura, MD; Xiongwei Zhu, PhD; Mark A. Smith, PhD
  Arch Neurol

Pittsburgh Compound B Imaging and Prediction of Progression From Cognitive Normality to Symptomatic Alzheimer Disease

Cognitive Decline and Brain Volume Loss as Signatures of Cerebral Amyloid-β Peptide Deposition Identified With Pittsburgh Compound B: Cognitive Decline Associated With Aβ Deposition

Transactive Response DNA-Binding Protein 43 Burden in Familial Alzheimer Disease and Down Syndrome

Characteristics and Surgical Outcomes of Patients With Refractory Magnetic Resonance Imaging–Negative Epilepsies

Status Epilepticus Associated With Subtentorial Posterior Fossa Lesions

Functional and Cognitive Outcome in Prolonged Refractory Status Epilepticus

Genotype-Phenotype Correlations in Charcot-Marie-Tooth Disease Type 2 Caused by Mitofusin 2 Mutations

Motor Phenotype of LRRK2 G2019S Carriers in Early-Onset Parkinson Disease

Heterogeneity in Infarct Patterns and Clinical Outcomes Following Internal Carotid Artery Occlusion

HLA-DRB1*1501 and Spinal Cord Magnetic Resonance Imaging Lesions in Multiple Sclerosis

High Striatal Amyloid β-Peptide Deposition Across Different Autosomal Alzheimer Disease Mutation Types

Quantitative Template for Subtyping Primary Progressive Aphasia